VERVE THERAPEUTICS INC. - COMMON STOCK

Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia

26 Apr 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease

04 Apr 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference

24 Mar 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference

23 Feb 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs

10 Jan 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer

29 Nov 2021 07:00:00 By Nasdaq GlobeNewswire

Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results

10 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates

09 Nov 2021 05:30:00 By Nasdaq GlobeNewswire

Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

21 Oct 2021 05:30:00 By Nasdaq GlobeNewswire